Man-Cai Fong1,2,3, Hung-Yu Chang1,3, Chun-Chieh Wang4, An-Ning Feng1,3, Wei-Shiang Lin2,5, Yen-Wen Wu6, Shih-Hsien Sung3,7, Jin-Long Huang3,8, Jen-Yuan Kuo9, Wei-Hsian Yin1,3. 1. Heart Center, Cheng Hsin General Hospital. 2. Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center. 3. Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei. 4. Division of Cardiology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan. 5. Departments of Medicine, Tri-Service General Hospital, Taipei. 6. Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City. 7. Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei. 8. Cardiovascular Center, Taichung Veterans General Hospital, Taichung. 9. Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Renin-angiotensin system inhibitors and beta-blockers are the initial treatment of choice for heart failure with reduced ejection fraction (HFrEF), whereas sacubitril/valsartan (SAC/VAL) and ivabradine are considered to second-line therapies. The eligibility of SAC/VAL and ivabradine according to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) labels, Taiwan National Health Insurance (TNHI) reimbursement regulations, and European Society of Cardiology (ESC) heart failure (HF) guidelines are diverse, and they may not fulfill the needs of real-world HFrEF patients. METHODS: Patients hospitalized for HF with left ventricular ejection fraction (LVEF) ≤ 40% were recruited from 21 hospitals in Taiwan between 2013 and 2014. The criteria for SAC/VAL and ivabradine according to the different regulations were applied. RESULTS: Of 1,474 patients, 86.8%, 29.4%, and 9.5% met the EMA/FDA label criteria, TNHI-regulation, and ESC guidelines for SAC/VAL, compared to 47.1%, 37.2%, and 45.6% for ivabradine, respectively. Ineligible reasons for the TNHI regulations included LVEF > 35% (19.9%, for SAC/VAL and ivabradine) and sinus rate < 75 beats per minute (bpm) (29.9%, for ivabradine). Although not meeting the TNHI regulations, patients with LVEF 35-40% had a similar 1-year mortality rate (15.6% vs. 15.8%, p = 0.876) to those with LVEF ≤ 35%, whereas patients with a sinus rate 70-74 bpm had a similar 1-year mortality rate (15.3% vs. 16.1%, p = 0.805) to those with a sinus rate ≥ 75 bpm. CONCLUSIONS: Approximately 70% and 63% of TSOC-HFrEF registry patients were ineligible for SAC/VAL and ivabradine, respectively, according to current TNHI regulations. Regardless of the eligibility for novel HFrEF medications, the high incidence of adverse events suggests that all patients should be treated cautiously.
BACKGROUND: Renin-angiotensin system inhibitors and beta-blockers are the initial treatment of choice for heart failure with reduced ejection fraction (HFrEF), whereas sacubitril/valsartan (SAC/VAL) and ivabradine are considered to second-line therapies. The eligibility of SAC/VAL and ivabradine according to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) labels, Taiwan National Health Insurance (TNHI) reimbursement regulations, and European Society of Cardiology (ESC) heart failure (HF) guidelines are diverse, and they may not fulfill the needs of real-world HFrEF patients. METHODS: Patients hospitalized for HF with left ventricular ejection fraction (LVEF) ≤ 40% were recruited from 21 hospitals in Taiwan between 2013 and 2014. The criteria for SAC/VAL and ivabradine according to the different regulations were applied. RESULTS: Of 1,474 patients, 86.8%, 29.4%, and 9.5% met the EMA/FDA label criteria, TNHI-regulation, and ESC guidelines for SAC/VAL, compared to 47.1%, 37.2%, and 45.6% for ivabradine, respectively. Ineligible reasons for the TNHI regulations included LVEF > 35% (19.9%, for SAC/VAL and ivabradine) and sinus rate < 75 beats per minute (bpm) (29.9%, for ivabradine). Although not meeting the TNHI regulations, patients with LVEF 35-40% had a similar 1-year mortality rate (15.6% vs. 15.8%, p = 0.876) to those with LVEF ≤ 35%, whereas patients with a sinus rate 70-74 bpm had a similar 1-year mortality rate (15.3% vs. 16.1%, p = 0.805) to those with a sinus rate ≥ 75 bpm. CONCLUSIONS: Approximately 70% and 63% of TSOC-HFrEF registry patients were ineligible for SAC/VAL and ivabradine, respectively, according to current TNHI regulations. Regardless of the eligibility for novel HFrEF medications, the high incidence of adverse events suggests that all patients should be treated cautiously.
Authors: Takeshi Kitai; Justin L Grodin; Robert J Mentz; Adrian F Hernandez; Javed Butler; Marco Metra; John J McMurray; Paul W Armstrong; Randall C Starling; Christopher M O'Connor; Karl Swedberg; W H Wilson Tang Journal: Eur J Heart Fail Date: 2016-09-16 Impact factor: 15.534
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur J Heart Fail Date: 2016-05-20 Impact factor: 15.534
Authors: Eric J Velazquez; David A Morrow; Adam D DeVore; Carol I Duffy; Andrew P Ambrosy; Kevin McCague; Ricardo Rocha; Eugene Braunwald Journal: N Engl J Med Date: 2018-11-11 Impact factor: 91.245
Authors: James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg Journal: Circulation Date: 2004-10-18 Impact factor: 29.690
Authors: Pratyaksh K Srivastava; Brian L Claggett; Scott D Solomon; John J V McMurray; Milton Packer; Michael R Zile; Akshay S Desai; Jean L Rouleau; Karl Swedberg; Gregg C Fonarow Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676